COMMUNIQUÉS West-GlobeNewswire

SeaSpine Announces Launch of Mariner® Outrigger® Revision System
31/07/2019
CARLSBAD, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]
Atlas Nanotech Opens First Revenue Stream
31/07/2019
Multipurpose contract signed with Gem Labs GUADALAJARA, Mexico, July 31, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – CSSI (Costas Inc.), DBA Atlas Nanotech, today memorialized an agreement with Laboratorios Gem S.A. de C [...]
Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
31/07/2019
REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), [...]
ChemoCentryx to Hold Second Quarter 2019 Financial Results Conference Call on Monday, August 5, 2019
31/07/2019
MOUNTAIN VIEW, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2019 financial results will be released after market close on Monday, August [...]
Stryker declares a $0.52 per share quarterly dividend
31/07/2019
Kalamazoo, Michigan, July 31, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.52 per share payable on October 31, 2019 to shareholders of record [...]
SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
31/07/2019
- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement - - Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative Breast, and Small Cell Lung Cancers and Acute [...]
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
31/07/2019
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada DUBLIN and LUGANO, July 31, 2019 -- Endo International plc (NASDAQ: ENDP), and Helsinn, a Swiss pharmaceutical group [...]
Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
31/07/2019
CORAL GABLES, Fla., July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with [...]
Forty Seven Inc. to Present at Canaccord Genuity 39th Annual Growth Conference
31/07/2019
MENLO PARK, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]
Align Technology Announces $200 Million Accelerated Stock Repurchase Program
31/07/2019
Joe Hogan, president and CEO, intends to personally purchase $1.0 million of Align’s common stock SAN JOSE, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ: ALGN) announced that it has entered [...]
Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
31/07/2019
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, [...]
Intercept to Announce Second Quarter 2019 Financial Results on August 7, 2019
31/07/2019
NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Pluristem and U.S. Department of Defense Present Positive Data from Studies Testing PLX-R18 as a Prophylactic Treatment for Acute Radiation Syndrome
31/07/2019
PLX-R18 demonstrated significant increase in survival rates and recovery of the three blood lineages Data is jointly presented at the 2019 Radiation Injury Treatment Network (RITN) Workshop HAIFA, Israel, July 31, 2019 [...]
Zynerba Pharmaceuticals to Present at Two Upcoming Conferences
31/07/2019
DEVON, Pa., July 31, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]
Selecta Biosciences to Present at Canaccord Genuity’s 39th Annual Growth Conference on August 7, 2019
31/07/2019
WATERTOWN, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune [...]
CB2 Insights Adds Former Johnson & Johnson Executive as Director
31/07/2019
TORONTO, July 31, 2019 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the [...]
Kaleido Biosciences to Present at the 39th Annual Canaccord Genuity Growth Conference
31/07/2019
LEXINGTON, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the potential of the microbiome organ to [...]
Tauriga Sciences Inc. to Integrate QR Codes into Future Product Package Design(s)
31/07/2019
New York, NY, July 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, [...]
Strongbridge Biopharma plc Reports Second Quarter 2019 Financial Results and Provides Corporate Update
31/07/2019
~ KEVEYIS ® (dichlorphenamide) Second Quarter 2019 Revenue of $6.1 Million ~ ~ Company on Track to Meet Full-Year 2019 KEVEYIS ® Revenue Guidance of $18 to $20 Million ~ ~ Enrollment in Phase 3 LOGICS Study for RECORLEV [...]

Pages